{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-016758","form_type":"8-K","ticker":"IDYA","cik":"0001676725","company_name":"IDEAYA Biosciences, Inc.","filed_at":"2024-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.079269+00:00","generated_at":"2026-06-05T23:13:24.336265+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"IDYA reports Q4 net loss $34M, cash $632.6M; multiple 2024 milestones","bullets":["Cash $632.6M at Dec 31, 2023; Jan 2024 ATM raised ~$352M gross ($342.3M net); runway into 2028.","Q4 net loss $34.0M (vs $24.2M); FY 2023 net loss $113.0M (vs $58.7M). R&D spend $38.8M Q4.","Targeting two Phase 2 efficacy updates for darovasertib in neoadjuvant uveal melanoma mid-2024, plus FDA guidance.","Gilead collaboration to evaluate IDE397 + Trodelvy in MTAP-deletion bladder cancer; FPI mid-2024.","Werner helicase IND filing targeted 2024; $7M milestone on clearance. GSK collaboration."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-016758","json":"https://secwatch.observer/filing/0000950170-24-016758.json","markdown":"https://secwatch.observer/filing/0000950170-24-016758.md","text":"https://secwatch.observer/filing/0000950170-24-016758.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676725/000095017024016758/0000950170-24-016758-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676725/000095017024016758/idya-20240220.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T23:13:24.336265+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b2162f2894150e2bbba3175233687624ec782179","claim":"IDEAYA Biosciences, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"On February 20, 2024, IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1676725/000095017024016758/0000950170-24-016758-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}